company background image
BLT

BLIS TechnologiesNZSE:BLT Stock Report

Market Cap

NZ$77.7m

7D

0%

1Y

-29.1%

Updated

19 Oct, 2021

Data

Company Financials
BLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends0/6

BLT Overview

BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.

Price History & Performance

Summary of all time highs, changes and price drops for BLIS Technologies
Historical stock prices
Current Share PriceNZ$0.061
52 Week HighNZ$0.054
52 Week LowNZ$0.086
Beta0.40
1 Month Change-7.58%
3 Month Change-15.28%
1 Year Change-29.07%
3 Year Change258.82%
5 Year Change22.00%
Change since IPO-93.84%

Recent News & Updates

Mar 08
Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)

Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)

How far off is BLIS Technologies Limited ( NZSE:BLT ) from its intrinsic value? Using the most recent financial data...

Feb 09
BLIS Technologies Limited (NZSE:BLT) Insiders Have Been Selling

BLIS Technologies Limited (NZSE:BLT) Insiders Have Been Selling

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

Jan 21
BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

BLIS Technologies (NZSE:BLT) has had a rough three months with its share price down 8.1%. But if you pay close...

Jan 03
I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With Ease

I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With Ease

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

BLTNZ PharmaceuticalsNZ Market
7D0%2.6%-0.1%
1Y-29.1%0.4%1.9%

Return vs Industry: BLT underperformed the NZ Pharmaceuticals industry which returned 0.4% over the past year.

Return vs Market: BLT underperformed the NZ Market which returned 1.9% over the past year.

Price Volatility

Is BLT's price volatile compared to industry and market?
BLT volatility
BLT Beta0.40
Industry Beta1.29
Market Beta1

Stable Share Price: BLT is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BLT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aBrian Watsonhttps://www.blis.co.nz

BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of infants and children, as well as for improving bad breath; and BLIS M18 for promoting the bacterial balance for dental health. Its product portfolio consists of DailyDefence, a daily probiotic to support throat immunity; DailyDefence Junior, a daily powder formulation to support ear, nose, and throat health of infants and small children; ThroatGuard PRO to give immunity support to help protect against winter ills; ElitePRO, a suite of WADA tested products for athletes; and TravelProtect to help support the immune system when travelling.

BLIS Technologies Fundamentals Summary

How do BLIS Technologies's earnings and revenue compare to its market cap?
BLT fundamental statistics
Market CapNZ$77.70m
Earnings (TTM)NZ$564.00k
Revenue (TTM)NZ$10.82m

138.6x

P/E Ratio

7.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLT income statement (TTM)
RevenueNZ$10.82m
Cost of RevenueNZ$1.88m
Gross ProfitNZ$8.94m
ExpensesNZ$8.38m
EarningsNZ$564.00k

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.00044
Gross Margin82.65%
Net Profit Margin5.21%
Debt/Equity Ratio1.5%

How did BLT perform over the long term?

See historical performance and comparison

Valuation

Is BLIS Technologies undervalued compared to its fair value and its price relative to the market?

138.64x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BLT is poor value based on its PE Ratio (138.6x) compared to the Oceanic Pharmaceuticals industry average (44.9x).

PE vs Market: BLT is poor value based on its PE Ratio (138.6x) compared to the NZ market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLT is overvalued based on its PB Ratio (13.7x) compared to the XO Pharmaceuticals industry average (3.5x).


Future Growth

How is BLIS Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

61.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIS Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has BLIS Technologies performed over the past 5 years?

58.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLT has a high level of non-cash earnings.

Growing Profit Margin: BLT's current net profit margins (5.2%) are lower than last year (14.8%).


Past Earnings Growth Analysis

Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by 58.8% per year.

Accelerating Growth: BLT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BLT had negative earnings growth (-64.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.4%).


Return on Equity

High ROE: BLT's Return on Equity (10%) is considered low.


Financial Health

How is BLIS Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BLT's short term assets (NZ$5.1M) exceed its short term liabilities (NZ$1.8M).

Long Term Liabilities: BLT's short term assets (NZ$5.1M) exceed its long term liabilities (NZ$332.0K).


Debt to Equity History and Analysis

Debt Level: BLT's debt to equity ratio (1.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BLT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BLT's debt is well covered by operating cash flow (709.6%).

Interest Coverage: BLT's interest payments on its debt are well covered by EBIT (142x coverage).


Balance Sheet


Dividend

What is BLIS Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Brian Watson

5.67yrs

Tenure

Mr. Brian D. Watson, B Com (Marketing), B Ph Ed, has been Chief Executive Officer of BLIS Technologies Limited since February 15, 2016. Mr. Watson has strong sales and marketing credentials and expertise....


Leadership Team

Experienced Management: BLT's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: BLT's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.


Top Shareholders

Company Information

BLIS Technologies Limited's employee growth, exchange listings and data sources


Key Information

  • Name: BLIS Technologies Limited
  • Ticker: BLT
  • Exchange: NZSE
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$77.702m
  • Shares outstanding: 1.27b
  • Website: https://www.blis.co.nz

Number of Employees


Location

  • BLIS Technologies Limited
  • 81 Glasgow Street
  • South Dunedin
  • Dunedin
  • 9012
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 15:39
End of Day Share Price2021/10/19 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.